Clinically, increased versican expression correlates to a decreased progression-free survival in prostate cancer (40), increased relapse in breast cancer (41), advanced disease and lymph node metastasis in adenocarcinomas of the lung (42), and is also diagnostically relevant in other cancers [reviewed in Ref. Here, VCAN is linked to breast cancer.